Lead drug candidate LB1148 is a phase 3-ready, oral drug with the potential to both reduce abdominal adhesions and help restore bowel function.

Science

Palisade Bio is leveraging more than three decades of academic research as well as 15 years of the company’s own internal efforts to advance therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage.

Read More

Lead drug candidate LB1148 is a phase 3-ready, oral drug with the potential to both reduce abdominal adhesions and help restore bowel function.

LB1148

Lead drug candidate LB1148 is a phase 3-ready, oral drug with the potential to both reduce abdominal adhesions and help restore bowel function following surgery, two complications that increase the time patients spend in hospitals. LB1148 has pipeline-in-a-product potential, given the array of various complications downstream of digestive enzyme damage that could be addressed by preserving intestinal integrity.

Read More

Lead drug candidate LB1148 is a phase 3-ready, oral drug with the potential to both reduce abdominal adhesions and help restore bowel function.

Guarding Intestinal Integrity

More than 30 years of groundbreaking scientific research conducted at the University of California at San Diego and other prestigious academic institutions supports the importance of guarding intestinal integrity to overall human health and highlights the medical complications that can occur when its intestinal mucosal barrier is disrupted.

Read More

Lead drug candidate LB1148 is a phase 3-ready, oral drug with the potential to both reduce abdominal adhesions and help restore bowel function.

Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that aid patients suffering with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset LB1148, is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 clinical trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in the return of bowel function and a decrease in the length of stay in ICU and hospital compared to placebo. Plans are underway to commence a pivotal, Phase 3 study of LB1148 in the second half of 2022. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with the chronic disruption to the gastrointestinal epithelial barrier.